Next Day Disclosure Return
Filed with HKEX · Stock code 9606 · · 6 pages · English
Duality Biotherapeutics, Inc. on 6ix
Earlier from Duality Biotherapeutics
- 2026 Interim report
- DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
- DualityBio (9606.HK) Announces 2025 Annual Results
- DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
- First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Later from Duality Biotherapeutics
- An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Inside information - update on the dynasty-BREAST02 global phase 3 clinical trial of trastuzumab pamirtecan
- Voluntary announcement - update on share repurchases and proposed increase in shareholding by chairman of the board
Follow Duality Biotherapeutics into a list and get an email when it puts out news.
Follow Duality Biotherapeutics